Prism Pharmaceuticals Inc., of King of Prussia, Pa., appointed Maurits Geerlings vice president of business development.

Pro-Pharmaceuticals Inc., of Newton, Mass., named Theodore Zucconi president and nominated him for a board position. The firm also appointed Anthony Squeglia chief financial officer and named Steven Schubert vice president of finance on a consulting basis.

Protox Therapeutics Inc., of Vancouver, British Columbia, appointed Martin Gleave chairman of its clinical advisory board (urology).

Resverlogix Corp., of Calgary, Alberta, named Stella Thompson to its board.

Shire plc, of Basingstoke, UK, appointed Sylvie Gregoire president of its Human Genetic Therapies business.

Solazyme, of South San Francisco, named Troy Campione senior vice president of business development.

Speedel, of Basel, Switzerland, appointed Klaus Dembowsky head of Speedel Experimenta, a late-stage research unit.

Synvista Therapeutics Inc., of Montvale, N.J., appointed Carl Mendel vice president of clinical development and chief medical officer.

Uluru Inc., of Addison, Texas, named Renaat Van den Hooff executive vice president of operations.

Velcura Therapeutics Inc., of Ann Arbor, Mich., appointed Richard Dyer executive vice president of product development.

Ventaira Pharmaceuticals Inc., of Columbus, Ohio, named Edward Ball, Rudolf Brenneisen, Steven Childers, Anthony Fox, Marianne Mann, Cynthia McCormick and John Morley to its scientific advisory board.

ViRexx Medical Corp., of Edmonton, Alberta, appointed Darrell Elliott director, chairman and interim CEO.

VLST Corp., of Seattle, appointed Consuelo Blosch vice president of clinical and regulatory and Dan Allison senior director of therapeutic design.

WaferGen Biosystems Inc., of Fremont, Calif., appointed Sharat Singh senior vice president of research and development and named Christopher Maki vice president of worldwide sales.

Zila Inc., of Phoenix, added David Goldman to its board.